RT Journal Article
SR Electronic
T1 Do post-COVID-19 patients need a second dose of vaccine?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.09.21255200
DO 10.1101/2021.04.09.21255200
A1 Jorg Taubel
A1 Christopher S Spencer
A1 Anne Freier
A1 Dorothée Camilleri
A1 Ibon Garitaonandia
A1 Ulrike Lorch
YR 2021
UL http://medrxiv.org/content/early/2021/04/13/2021.04.09.21255200.abstract
AB Vaccination forms a key part of public health strategies to control the spread of SARS-CoV-2 globally. In the UK, two vaccines (BNT162b2-mRNA produced by Pfizer, and ChAdOx-1-S produced by Oxford-AstraZeneca) have been licensed to date, and their administration is prioritised according to individual risk. This study forms part of a longitudinal assessment of participants’ SARS-CoV-2-specific antibody levels before and after vaccination. Our results confirm that there is little quantitative difference in the antibody titres achieved by the two vaccines. Our results also suggest that individuals who have previously been infected with SARS-CoV-2 achieve markedly higher antibody titres than those who are immunologically naïve. This finding is useful to inform vaccine prioritisation strategies in the future: individuals with no history of SARS-CoV-2 infection should be prioritised for a second vaccine inoculation.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIRAS ID: 281788Funding StatementThis work was self-funded by Richmond Pharmacology LtdAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NRES Committee (West Midlands - Edgbaston)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request.